Literature DB >> 34011987

A physicochemical assessment of the thermal stability of dextrin-colistin conjugates.

Emilie Chiron1, Mathieu Varache1,2, Joana Stokniene1, David W Thomas1, Elaine L Ferguson3.   

Abstract

Attachment of polysaccharide carriers is increasingly being used to achieve precision delivery and improved effectiveness of protein and peptide drugs. Although it is clear that their clinical effectiveness relies on the purity and integrity of the conjugate in storage, as well as following administration, instability of polysaccharide-based conjugates can reduce the protective efficacy of the polymer, which may adversely affect the bioactive's potency. As a model, these studies used dextrin-colistin conjugates, with varying degrees of polymer modification (1, 2.5 and 7.5 mol% succinoylation) to assess the effect of storage temperature (- 20, 4, 21 and 37 °C) and duration (up to 12 months) on saccharide and colistin release and antimicrobial activity. Estimation of the proportion of saccharide release (by comparison of area under the curve from size exclusion chromatograms) was more pronounced at higher temperatures (up to 3 and 35% at - 20 °C and 37 °C, respectively after 12 months), however, repeated freeze-thaw did not produce any measurable release of saccharides, while addition of amylase (20, 100, 500 IU/L) caused rapid release of saccharides (> 70% total within 24 h). At all temperatures, conjugates containing the lowest degree of succinoylation released the highest proportion of free colistin, which increased with storage temperature, however no trend in saccharide release was observed. Despite the clear physical effects of prolonged storage, antimicrobial activity of all samples was only altered after storage at 37 °C for 12 months (> threefold decreased activity). These results demonstrate significant release of saccharides from dextrin-colistin conjugates during prolonged storage in buffered solution, especially at elevated temperature, which, in most cases, did not affect antimicrobial activity. These findings provide vital information about the structure-activity relationship of dextrin-colistin conjugates, prior to full-scale commercial development, which can subsequently be applied to other polysaccharide-protein and -peptide conjugates.

Entities:  

Year:  2021        PMID: 34011987     DOI: 10.1038/s41598-021-89946-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  21 in total

1.  Dextrin-colistin conjugates as a model bioresponsive treatment for multidrug resistant bacterial infections.

Authors:  Elaine L Ferguson; Ernest Azzopardi; Jessica L Roberts; Timothy R Walsh; David W Thomas
Journal:  Mol Pharm       Date:  2014-11-17       Impact factor: 4.939

2.  Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Jennifer Le; Elizabeth Dodds Ashley; Melinda M Neuhauser; Jack Brown; Chris Gentry; Michael E Klepser; Ann Marie Marr; Daryl Schiller; Joshua N Schwiesow; Sally Tice; Heather L VandenBussche; G Christopher Wood
Journal:  Pharmacotherapy       Date:  2010-06       Impact factor: 4.705

3.  Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.

Authors:  Stephanie J Wallace; Jian Li; Craig R Rayner; Kingsley Coulthard; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

4.  Localized cutaneous polyvinylpyrrolidone storage disease mimicking cheilitis granulomatosa.

Authors:  Ching-Chi Chi; Shu-Hui Wang; Tseng-tong Kuo
Journal:  J Cutan Pathol       Date:  2006-06       Impact factor: 1.587

Review 5.  Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?

Authors:  Andreas Baumann; Dietrich Tuerck; Saileta Prabhu; Leslie Dickmann; Jennifer Sims
Journal:  Drug Discov Today       Date:  2014-06-11       Impact factor: 7.851

6.  Polymer masked-unmasked protein therapy. 1. Bioresponsive dextrin-trypsin and -melanocyte stimulating hormone conjugates designed for alpha-amylase activation.

Authors:  Ruth Duncan; Helena R P Gilbert; Rodrigo J Carbajo; María J Vicent
Journal:  Biomacromolecules       Date:  2008-03-19       Impact factor: 6.988

7.  Stability of colistimethate sodium in aqueous solution.

Authors:  A M Healan; W Gray; E J Fuchs; J M Griffiss; R A Salata; J Blumer
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

Review 8.  PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.

Authors:  Inge A Ivens; William Achanzar; Andreas Baumann; Annamaria Brändli-Baiocco; Joy Cavagnaro; Maggie Dempster; B Olympe Depelchin; Armando R Irizarry Rovira; Laura Dill-Morton; Joan H Lane; Birgit M Reipert; Theodora Salcedo; Becky Schweighardt; Laurie S Tsuruda; Peter L Turecek; Jennifer Sims
Journal:  Toxicol Pathol       Date:  2015-08-03       Impact factor: 1.902

Review 9.  Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics.

Authors:  Johan J F Verhoef; John F Carpenter; Thomas J Anchordoquy; Huub Schellekens
Journal:  Drug Discov Today       Date:  2014-09-07       Impact factor: 7.851

10.  Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Kingsley Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.